Medical/Pharmaceuticals
Minghui Pharmaceutical to Present the Phase I/II Study of MHB088C (B7-H3 ADC) for the Treatment of Patients with Recurrent or Metastatic Solid Tumors in Late-breaking Oral Presentation at the 2024 ASCO Annual Meeting
SHANGHAI, May 8, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company focused on autoimmune diseases and oncology, will feature Dr.Lin Shen from Beijing Cancer Hospital at the upcoming ASCO Annual Meeting inChicago. Dr. Shen will present the results f...
NSG BioLabs Fuels Biotech Innovation in Singapore and Southeast Asia Through Partnerships with EnterpriseSG and Merck, Alongside Investments from Celadon Partners and ClavystBio
* Since 2019, NSG BioLabs has been a leader in co-working lab spaces in Singapore, and has nurtured over 40 biotech companies, of which the startups have achieved nearlyUS$400 million funding in total alongside significant business milestones * NSG BioLabs' partnerships with EnterpriseSG and ...
Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau
SHANGHAI, May 8, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Pharmaceutical Administration ...
Newly Published Data in JAMA Cardiology Demonstrates Favorable Long-term Effects of the Corvia Atrial Shunt in Heart Failure Patients
Two years of echocardiographic data affirm positive effects of atrial shunt therapy on heart structure and function TEWKSBURY, Mass., May 8, 2024 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JAMA Cardi...
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
GAITHERSBURG, Md., May 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disease...
Research Results on Jolly Good's Medical VR Will Be Presented for the First Time in the U.S. - Revealing Training VR for HALO Procedures at Large-Scale VR Seminar, SAEM2024
BROOKLINE, Mass., May 7, 2024 /PRNewswire/ -- Jolly Good US Inc. is proud to announce the groundbreaking debut of research findings on its Medical Virtual Reality (VR) platform inthe United States. This unveiling will take place at the annual meeting of the Society for Academic Emergency Medicine...
Seragon Completes Pre-Clinical Study of Aging Intervention Candidate SRN-901
IRVINE, Calif., May 7, 2024 /PRNewswire/ -- Seragon Biosciences, Inc. today announced the completion of a pre-clinical study on its novel anti-aging candidate, SRN-901. This pivotal study, conducted in mice, was undertaken to evaluate the impact of SRN-901 on aging as well as various health marke...
FDA Grants Orphan Drug Designation to 9MW2821
SHANGHAI, May 7, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Adminis...
Meihua International Medical Technologies Co., Ltd. to Present at the Emerging Growth Conference on May 9, 2024
Meihua International Medical Technologies Co., Ltd. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. YANGZHOU, China, May 7, 2024 /PRNewswire/ -- Meihua International Medical Tech...
Imaging Endpoints Unveils New Initiative with Revolution Endpoints™, an Investment Subsidiary to Accelerate Innovation and Growth
SCOTTSDALE, Ariz., May 7, 2024 /PRNewswire/ -- Imaging Endpoints (IE), a global leader in Imaging CRO technologies and services, has announced the formation of a new subsidiary, Revolution Endpoints, focused on leveraging the Company's strong leadership and financial position to acquire synergist...
/C O R R E C T I O N -- The Adecco Group/
In the news release, AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange, issued07-May-2024 by The Adecco Group over PR Newswire, we are advised by the client that the headline should read "The Adecco Group: Q1 24 Results" rather than "[AD HOC ANNOUNCEMENT pursuant to Art....
Sciwind Biosciences and HK inno.N Corporation Announce Licensing and Partnership Agreement for Ecnoglutide Injection (XW003) in South Korea
HANGZHOU, China and SEOUL, South Korea, May 7, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation, a South Korean commercial stage pharmaceutical company (KOSDAQ: 195940),...
2024 World Brain Day Dedicated to Brain Health and Prevention
LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place onMonday, July 22. The goal is to raise critical awareness to prevent brain disease in all corners of t...
GC Genome to Present New Clinical Data on Colorectal Cancer Detection at the ASCO Annual Meeting 2024
YONGIN, South Korea, May 7, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) Annual ...
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC)as Monotherapy for Advanced Gastric Cancer
SAN FRANCISCO and SUZHOU, China, May 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
HTL Biotechnology, market leader in biopolymers, acquires the Modern Meadow's human recombinant collagen platform for beauty and biomedical applications
JAVENÉ, France, May 6, 2024 /PRNewswire/ -- HTL Biotechnology strengthens its position as a global leader in the production and development of pharmaceutical-grade biopolymers by acquiring the beauty and biomedical division of American company Modern Meadow (Nutley, NJ). Notably, this acquisitio...
ThinkCyte Launches New Website and Showcases VisionSortTM at Global Events
TOKYO, May 7, 2024 /PRNewswire/ -- ThinkCyte today announced that it will be presenting at three major international scientific conferences in the first week of May and the launch of itsupdated website. The company will have a presence at the American Society for Immunology (AAI) fromMay 3rd to 7...
Datasea Pre-Announces Estimated Revenue of $12.5 Million for April 2024 Supporting its Prior Revenue Guidance of $86 Million for Fiscal 2024
DTSS on Track to Achieve Record Revenue for Fiscal 2024 as it Further Penetrates China's$528 Billion 5G Market BEIJING, May 6, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada and engaged in innovative business seg...
PolyU researchers create 2D all-organic perovskites and demonstrate potential use in 2D electronics
HONG KONG, May 6, 2024 /PRNewswire/ -- Perovskites are among the most researched topics in materials science. Recently, a research team led byProf. LOH Kian Ping, Chair Professor of Materials Physics and Chemistry and Global STEM Professor of the Department of Applied Physics of The Hong Kong Po...
Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting
SUZHOU, China, May 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from the clinical study conducted inChina (JSKN003-102) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, will be presente...
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00